Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics
Jan 20, 08:48 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.